News articles about Gemphire Therapeutics (NASDAQ:GEMP) have trended somewhat positive recently, Accern reports. The research firm identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Gemphire Therapeutics earned a news sentiment score of 0.09 on Accern’s scale. Accern also gave headlines about the company an impact score of 45.9752298337593 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

These are some of the news headlines that may have impacted Accern Sentiment’s analysis:

Gemphire Therapeutics (NASDAQ:GEMP) traded down $2.36 during mid-day trading on Thursday, reaching $6.27. The company had a trading volume of 1,724,000 shares, compared to its average volume of 109,148. The company has a market cap of $93.68, a PE ratio of -1.86 and a beta of 3.90. Gemphire Therapeutics has a fifty-two week low of $6.16 and a fifty-two week high of $21.59. The company has a debt-to-equity ratio of 1.00, a current ratio of 4.17 and a quick ratio of 4.17.

Gemphire Therapeutics (NASDAQ:GEMP) last released its quarterly earnings data on Monday, November 13th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.14). analysts predict that Gemphire Therapeutics will post -3.31 EPS for the current year.

GEMP has been the topic of several recent research reports. Canaccord Genuity restated a “buy” rating on shares of Gemphire Therapeutics in a research note on Friday, October 13th. Zacks Investment Research upgraded Gemphire Therapeutics from a “sell” rating to a “hold” rating and set a $11.00 price target on the stock in a research note on Monday, October 16th. Roth Capital initiated coverage on Gemphire Therapeutics in a research note on Thursday, October 19th. They issued a “buy” rating and a $30.00 price target on the stock. Piper Jaffray Companies restated an “overweight” rating and issued a $22.00 price target on shares of Gemphire Therapeutics in a research note on Friday, October 27th. Finally, HC Wainwright restated a “buy” rating and issued a $22.00 price target (up previously from $21.00) on shares of Gemphire Therapeutics in a research note on Tuesday, November 14th. One research analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $23.17.

COPYRIGHT VIOLATION NOTICE: This article was first reported by Daily Political and is owned by of Daily Political. If you are reading this article on another site, it was illegally stolen and reposted in violation of U.S. and international copyright legislation. The original version of this article can be viewed at

About Gemphire Therapeutics

Gemphire Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat cardiovascular and metabolic diseases. It is developing its product candidate, gemcabene (CI-1027), which is a once-daily, oral therapy for patients who are unable to achieve normal levels of low-density lipoprotein cholesterol (LDL-C) or triglycerides with approved therapies, primarily statin therapy.

Insider Buying and Selling by Quarter for Gemphire Therapeutics (NASDAQ:GEMP)

Receive News & Ratings for Gemphire Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemphire Therapeutics and related companies with's FREE daily email newsletter.